The drug pipeline of Priavoid is composed of 7 compounds in development with 6 CNS diseases:

  • Alzheimer’s disease
  • Neuropathic pain
  • Amyotrophic lateral sclerosis
  • Tauopathies
  • Huntington’s disease
  • Parkinson’s disease



Our current focus is on Phase II clinical trial of PRI-002, a synthetic all-D-peptide for causal treatment of Alzheimer’s disease.


Thus, PRI-002 has three unique selling propositions (USPs):


New mechanism of action
Specific elimination of toxic Aβ oligomers

New drug substance class
Synthetic all-D-peptide

Oral drug administration
Protease resistant

Intervention Strategy

Intervention Strategy

Priavoid follows a completely new strategy for treatment of Alzheimer’s disease.

We have developed stable D-peptides that are able to overcome the blood-brain barrier, do not interfere with formation or clearance with normal non-toxic Abeta monomers, but specifically eliminate cytotoxic Abeta oligomers.


Partnering is a key component of Priavoids strategy

Cookie Preference

Please select an option. You can find more information about the consequences of your choice at Help.

Select an option to continue

Your selection was saved!



To continue, you must make a cookie selection. Below is an explanation of the different options and their meaning.

  • Accept all cookies:
    All cookies such as tracking and analytics cookies.
  • Accept first-party cookies only:
    Only cookies from this website.
  • Reject all cookies:
    No cookies except for those necessary for technical reasons are set.

You can change your cookie setting here anytime: Privacy Policy. Legal Notice